Bayer clotting drug meets late-stage study’s goal

Published



TRENTON, N.J. (AP) — Bayer HealthCare Pharmaceuticals said Tuesday that its experimental, genetically engineered treatment for the most common type of bleeding disorder hemophilia met its main goal of reducing treatment frequency in a late-stage patient study.

The medicine, called BAY 94-9027, helped prevent damaging internal bleeding in patients when given less frequently than standard treatments, which many patients need every other day. Bayer’s treatment helps prevent bleeding episodes when infused — or given through a slow intravenous drip through a tube — as a preventive treatment twice per week, every five days and even every seven days. The medicine also stopped bleeding when it did occur.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.